BACKGROUND: Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) when added to chemotherapy. Little is known about factors associated with receipt of bevacizumab, or whether bevacizamab is associated with increased toxicity when added to chemotherapy. PATIENTS AND METHODS: We conducted a prospective study of patients aged ≥65 years, which evaluated the association between geriatric assessment (GA) metrics and chemotherapy toxicity. We examined differences in characteristics and outcomes of patients with CRC and NSCLC cancers who received bevacizumab with chemotherapy versus chemotherapy alone. RESULTS: From a total of 207 patients, 27 (13%) received bevacizumab plus chemotherapy and 180 (87%) received chemotherapy alone. Groups were similar in sociodemographic and cancer characteristics. There were no baseline differences in GA domains except that patients with heart disease were less likely to receive bevacizumab (4% vs. 26%, p = .01). Seventy-eight percent of patients who had bevacizumab had grade 3-5 toxicity compared to only 57% who received chemotherapy alone (p = .06). Patients receiving bevacizumab were more likely to develop grade 3 hypertension than those who received chemotherapy alone (15% vs. 2%, p < .01). In multivariable analysis, factors associated with grade 3 or more toxicity included: bevacizumab (OR: 2.86, p = .04), CRC (OR: 2.54, p < .01), and baseline anemia (OR: 2.58, p = .03). CONCLUSION: Heart disease was more common in those who did not receive bevacizumab. Older patients who receive bevacizumab with chemotherapy have a higher odds of developing a grade 3-5 toxicity compared with those who receive chemotherapy alone.
BACKGROUND:Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) when added to chemotherapy. Little is known about factors associated with receipt of bevacizumab, or whether bevacizamab is associated with increased toxicity when added to chemotherapy. PATIENTS AND METHODS: We conducted a prospective study of patients aged ≥65 years, which evaluated the association between geriatric assessment (GA) metrics and chemotherapy toxicity. We examined differences in characteristics and outcomes of patients with CRC and NSCLC cancers who received bevacizumab with chemotherapy versus chemotherapy alone. RESULTS: From a total of 207 patients, 27 (13%) received bevacizumab plus chemotherapy and 180 (87%) received chemotherapy alone. Groups were similar in sociodemographic and cancer characteristics. There were no baseline differences in GA domains except that patients with heart disease were less likely to receive bevacizumab (4% vs. 26%, p = .01). Seventy-eight percent of patients who had bevacizumab had grade 3-5 toxicity compared to only 57% who received chemotherapy alone (p = .06). Patients receiving bevacizumab were more likely to develop grade 3 hypertension than those who received chemotherapy alone (15% vs. 2%, p < .01). In multivariable analysis, factors associated with grade 3 or more toxicity included: bevacizumab (OR: 2.86, p = .04), CRC (OR: 2.54, p < .01), and baseline anemia (OR: 2.58, p = .03). CONCLUSION:Heart disease was more common in those who did not receive bevacizumab. Older patients who receive bevacizumab with chemotherapy have a higher odds of developing a grade 3-5 toxicity compared with those who receive chemotherapy alone.
Authors: Arti Hurria; Supriya Gupta; Marjorie Zauderer; Enid L Zuckerman; Harvey J Cohen; Hyman Muss; Miriam Rodin; Katherine S Panageas; Jimmie C Holland; Leonard Saltz; Mark G Kris; Ariela Noy; Jorge Gomez; Ann Jakubowski; Clifford Hudis; Alice B Kornblith Journal: Cancer Date: 2005-11-01 Impact factor: 6.860
Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245
Authors: Suresh S Ramalingam; Suzanne E Dahlberg; Corey J Langer; Robert Gray; Chandra P Belani; Julie R Brahmer; Alan B Sandler; Joan H Schiller; David H Johnson Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544
Authors: Frank A Scappaticci; Jamey R Skillings; Scott N Holden; Hans-Peter Gerber; Kathy Miller; Fairooz Kabbinavar; Emily Bergsland; James Ngai; Eric Holmgren; Jiuzhou Wang; Herbert Hurwitz Journal: J Natl Cancer Inst Date: 2007-08-08 Impact factor: 13.506
Authors: Nikki M Carroll; Thomas Delate; Alex Menter; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Elizabeth T Loggers; Debra P Ritzwoller Journal: J Oncol Pract Date: 2015-06-09 Impact factor: 3.840
Authors: Daneng Li; Linda M McCall; Olwen M Hahn; Clifford A Hudis; Harvey J Cohen; Hyman B Muss; Aminah Jatoi; Jacqueline M Lafky; Karla V Ballman; Eric P Winer; Debu Tripathy; Bryan Schneider; William Barry; Maura N Dickler; Arti Hurria Journal: Breast Cancer Res Treat Date: 2018-05-22 Impact factor: 4.872
Authors: J Feliu; V Heredia-Soto; R Gironés; B Jiménez-Munarriz; J Saldaña; C Guillén-Ponce; M J Molina-Garrido Journal: Clin Transl Oncol Date: 2019-06-25 Impact factor: 3.405
Authors: A W Castleberry; U Güller; I Tarantino; M F Berry; L Brügger; R Warschkow; T Cerny; C R Mantyh; D Candinas; M Worni Journal: J Gastrointest Surg Date: 2014-04-15 Impact factor: 3.452
Authors: Jun Jun Olsen; Sebastian Öther-Gee Pohl; Abhijeet Deshmukh; Malini Visweswaran; Natalie C Ward; Frank Arfuso; Mark Agostino; Arun Dharmarajan Journal: Clin Biochem Rev Date: 2017-11
Authors: J P Metges; M A Lebot; R Faroux; F Riaud; E Gamelin; O Capitain; V Guérin Meyer; P Leynia; J Y Douillard; H Senellart; S Rochard; C Louvigné; L Campion; O Dupuis; C Grollier; N A Achour; B Person; J L Raoul; E Boucher; C Bertrand; J F Ramée; L Guivarch; P L Etienne; S Roussel; H Desclos; M N Julien; M I Labarre; V Klein; R Bessard; C Stampfli; F Royet; J Faycal; S Gouva; G Le Bihan; M Couturier; A Gourlaouen; C Bertholom; M Porneuf; E Jobard; E Peguet; D Grasset; J F Bouret; V Bicheler; A Ulvoas; L Miglianico; C Chouzenoux; P Deguiral; L Derenne; D Martin; P Michel Langlet; C Bodin; V Rossi; S Barré; O Cojocarasu; C Naveau Ploux; A M Vidal; I Cumin; J Egreteau; A Brouard; T Matysiak Budnik; P Thomaré; A S Le Bris Michel; G Piriou; R Largeau; C Elhannani; E Crespeau; F Suberville; H Bourgeois; C Riche; D Déniel Lagadec; F Marhuenda; F Grudé Journal: Oncologie (Paris) Date: 2014-12-21 Impact factor: 0.333